5.76
前日終値:
$5.53
開ける:
$5.675
24時間の取引高:
403.21K
Relative Volume:
0.87
時価総額:
$163.72M
収益:
$42.35M
当期純損益:
$-78.67M
株価収益率:
-2.0454
EPS:
-2.8161
ネットキャッシュフロー:
$-63.18M
1週間 パフォーマンス:
-3.52%
1か月 パフォーマンス:
-16.28%
6か月 パフォーマンス:
-22.79%
1年 パフォーマンス:
-61.45%
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
名前
Arcturus Therapeutics Holdings Inc
セクター
電話
(858) 900-2660
住所
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ARCT
Arcturus Therapeutics Holdings Inc
|
5.76 | 157.18M | 42.35M | -78.67M | -63.18M | -2.8161 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-18 | 開始されました | B. Riley Securities | Buy |
| 2026-01-23 | 開始されました | Roth Capital | Buy |
| 2025-10-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-10-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-09-04 | 再開されました | H.C. Wainwright | Buy |
| 2025-05-28 | 開始されました | Scotiabank | Sector Outperform |
| 2025-01-28 | 開始されました | BTIG Research | Buy |
| 2024-08-12 | 開始されました | Leerink Partners | Outperform |
| 2023-12-13 | 開始されました | Canaccord Genuity | Buy |
| 2023-07-24 | 開始されました | William Blair | Outperform |
| 2023-05-11 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | 再開されました | Wells Fargo | Overweight |
| 2022-11-10 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | アップグレード | Citigroup | Neutral → Buy |
| 2022-11-02 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-08-10 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-05-11 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-01-31 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | ダウングレード | Goldman | Neutral → Sell |
| 2021-08-10 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-06-25 | 再開されました | Goldman | Neutral |
| 2021-06-21 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-02-17 | ダウングレード | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | 開始されました | Wells Fargo | Overweight |
| 2020-12-29 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-12-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | ダウングレード | ROTH Capital | Buy → Sell |
| 2020-12-08 | 繰り返されました | B. Riley Securities | Buy |
| 2020-12-07 | 繰り返されました | B. Riley Securities | Buy |
| 2020-10-26 | 開始されました | Barclays | Overweight |
| 2020-10-06 | 開始されました | Citigroup | Buy |
| 2020-08-26 | 開始されました | Piper Sandler | Overweight |
| 2020-07-30 | 再開されました | ROTH Capital | Buy |
| 2020-07-16 | 開始されました | Raymond James | Outperform |
| 2020-07-13 | 開始されました | B. Riley FBR | Buy |
| 2020-06-09 | ダウングレード | WBB Securities | Buy → Hold |
| 2020-02-11 | 開始されました | Robert W. Baird | Outperform |
| 2020-02-07 | 開始されました | Guggenheim | Buy |
| 2020-02-06 | 開始されました | Guggenheim | Buy |
| 2019-04-05 | 開始されました | H.C. Wainwright | Buy |
| 2018-09-20 | アップグレード | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Arcturus Therapeutics Holdings Inc (ARCT) 最新ニュース
Arcturus Therapeutics Holdings Inc - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Cash Flow - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arcturus Therapeutics Holdings Inc. (ARCT) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
ARCT|Arcturus Therapeutics Holdings Inc|Price:5.530|Chg%:-0.260 - TradingKey
Arcturus Therapeutics Holdings Inc. Revenue Breakdown – NASDAQ:ARCT - TradingView
Arcturus Therapeutics Holdings Inc (ARCT) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - BioSpace
Arcturus: Now That It's Come This Low, It's Time To Buy And Hold (NASDAQ:ARCT) - Seeking Alpha
Arcturus Therapeutics Holdings Inc (ARCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Understanding Momentum Shifts in (ARCT) - Stock Traders Daily
Is Arcturus Therapeutics' ARCT-032 a Game Changer for Cystic Fibrosis - Kavout | AI
ARCT Should I Buy - Intellectia AI
Arcturus Therapeutics (ARCT) Q1 2025 earnings summary - Quartr
BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Arcturus Therapeutics (ARCT) Reports Progress in Q1 2026 Earnings Call - GuruFocus
Price to sales forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView
If You Invested $1,000 in Arcturus Therape (ARCT) - Stock Titan
ARCTArcturus Therapeutics Holdings Inc Latest SEC Filings - Finviz
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar? - Yahoo Finance
This Honeywell Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
Thermo Fisher, Arcturus partner on Phase III ARCT-032 cystic fibrosis trial - Yahoo Finance
ARCT Initiates Coverage by Freedom Broker -- Rating Set to Buy - GuruFocus
Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy - Benzinga
Arcturus Therapeutics Holdings Inc. And Thermo Fisher Scientific Inc. Announce Strategic Collaboration To Advance ARCT-032 For Cystic Fibrosis - marketscreener.com
Arcturus rises on pact with Thermo Fisher for cystic fibrosis therapy - Seeking Alpha
Freedom Capital Markets Initiates Arcturus Therapeutics(ARCT.US) With Buy Rating, Announces Target Price $27 - Moomoo
Arcturus Therapeutics Announces Thermo Fisher mRNA Partnership - TipRanks
Arcturus partners with Thermo Fisher for cystic fibrosis drug By Investing.com - Investing.com Nigeria
Arcturus Therapeutics, Thermo Fisher Scientific to Collaborate on Advancing ARCT-032 in Cystic Fibrosis - marketscreener.com
Arcturus partners with Thermo Fisher for cystic fibrosis drug - Investing.com
Thermo Fisher to back Arcturus (NASDAQ: ARCT) ARCT-032 Phase 3 and manufacturing - Stock Titan
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis - Yahoo Finance
Arcturus Therapeutics Initiated at Buy by Freedom Broker - Moomoo
Avoiding Lag: Real-Time Signals in (ARCT) Movement - Stock Traders Daily
Price to earnings forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView
ARCT Q1 2026 Earnings: Narrower-than-expected loss as pipeline advances without revenueDividend Increase Stocks - dars.gov.et
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView
Arcturus Therapeutics Holdings Inc. (ARCT) Investigation: Bronste - The National Law Review
Enterprise value to EBIT forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Arcturus Therapeutics Holdings, Inc. Actuals & Estimates (NASDAQ:ARCT) - TradingView
ARCT Forecast — Price Target — Prediction for 2027 - TradingView
Arcturus Therapeutics Holdings Inc (ARCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):